Positive Clinical Study Results for Cellmid's Hair Growth Product Using Novel FGF5 Inhibitor

21-Apr-2015 - Cellmid Limited has received strong positive results in all measured areas of its independently conducted, randomized, blinded and placebo controlled human clinical study of the évolis ONE formulation. The 32 patient study was conducted with Cellmid’s novel and proprietary FGF5 inhibitor ...

Cellmid records positive data in midkine antibody study in kidney disease

30-Jan-2013 - Cellmid Limited has completed its first in-life diabetic nephropathy study with the Company’s anti-midkine antibodies (MK-Ab) in a mouse model of the disease. Two of Cellmid’s proprietary MK-Ab’s were tested. Both antibodies reduced kidney damage significantly, as assessed by functional and ...

Cellmid completed GMP manufacture of Midkine test

04-Aug-2011 - Cellmid Limited has completed technology transfer in relation to its midkine blood test (MK ELISA) and the test kits have been successfully produced in a GMP compliant environment in AsureQuality’s fully accredited facility in Melbourne.Transitioning from a development phase to fully GMP ...

Cellmid Signs Antibody Humanisation Collaboration with Antitope

15-Apr-2011 - Cellmid Limited has signed a collaboration agreement with Antitope Ltd for the humanisation of its lead therapeutic monoclonal antibody candidate. The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine antibody, using Cellmid’s patented sequence and ...

Cellmid completes Proof of Concept Study for Heart Attack

Animal study demonstrates midkine treatment reduces heart muscle death by 27% following heart attack

13-Apr-2011 - Cellmid Limited has completed its milestone preclinical studies into the efficacy of midkine (MK) for the treatment of acute myocardial infarction (AMI). Total dose of 0.18 mg/kg MK performed best and reduced the area of heart muscle damage by approximately 27% when compared to untreated animals ...